A JAPANESE, PHASE 3, OPEN-LABEL, 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY WITH RENAL IMPAIRMENT OR POST-HERPETIC NEURALGIA WITH RENAL IMPAIRMENT
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Mirogabalin (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Adverse reactions; Registrational
- Sponsors Daiichi Sankyo Company
- 01 Aug 2018 Results of pool data from four trials, were published in the Clinical Pharmacology in Drug Development.
- 13 Apr 2017 Status changed from active, no longer recruiting to completed.
- 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.